Presentation is loading. Please wait.

Presentation is loading. Please wait.

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations 

Published byRudolph Harvey Modified over 6 years ago

Similar presentations

Presentation on theme: "Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations "— Presentation transcript:

1 Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations  Yen-Fu Chen, MD, Min-Shu Hsieh, MD, Shang-Gin Wu, MD, Yih-Leong Chang, MD, Jin-Yuan Shih, MD, PhD, Yi-Nan Liu, PhD, Meng- Feng Tsai, PhD, Tzu-Hsiu Tsai, MD, Chong-Jen Yu, MD, PhD, James Chih-Hsin Yang, MD, PhD, Pan-Chyr Yang, MD, PhD  Journal of Thoracic Oncology  Volume 9, Issue 8, Pages (August 2014) DOI: /JTO Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Hematoxylin and eosin stain and Immunohistochemical staining (ROS1 D4D6) of ROS1 fusion-positive lung adenocarcinoma. (A, B) Case 3, surgical specimen with CD74-ROS1 fusion had diffuse and strongly (3+) cytoplasmic granular stain (100X). (C,D) Case 4, SDC4-ROS1 fusion tumors (100X) showed strong (3+), diffuse ROS1 expression in the cytoplasma. (E,F) Case 6, ROS1 protein was expressed diffusely in the cytoplasm of CD74-ROS1 fusion cell block specimen (400X). Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 A, Kaplan-Meier survival curve of relapse-free survival for surgical patients with lung adenocarcinoma (n = 160) in different molecular cohorts. There was no significant survival difference among the ROS1 fusion-positive patients (dotted line), epidermal growth factor receptor (EGFR) mutation-positive patients (thick line), echinoderm microtubule-associated protein-like 4 (EML4-ALK) fusion patients (thin dashed line), KRAS (thick dashed line) mutation, and quadruple-negative patients (thin line). (B) Kaplan-Meier survival curve of overall survival for surgical patients with lung adenocarcinoma (n = 160) with different molecular cohorts. There was no significant survival difference among ROS1 fusion-positive patients (dotted line), EGFR mutation-positive patients (thick line), EML4-ALK fusion patients (thin dashed line), KRAS (thick dashed line), and quadruple negative patients (thin line). MST, median survival time (months). The p value was calculated using the log-rank test. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Kaplan-Meier survival curve of overall survival (OS) for stage IV lung adenocarcinoma patients (n = 332) with different molecular cohorts. Epidermal growth factor receptor (EGFR) mutation patients (thick line) had longer OS than patients with the echinoderm microtubule-associated protein-like 4 (EML4-ALK) fusion (thin dashed line; p = 0.039), KRAS mutation (thick dashed line; p = 0.011), and the quadruple-negative patients (thin line; p < 0.001). The ROS1 fusion-positive patients (dotted line) had potentially worse outcome than EGFR mutation patients (green line; p = 0.139), but they did not have survival differences compared with the EML4-ALK fusion, KRAS mutation, and quadruple-negative cohorts (p = 0.656, 0.435, and 0.758, respectively). MST, median survival time (months). The p value was calculated using the log-rank test. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations "

Similar presentations

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer  Wu-Wei Lai, MD, Fen-Fen Chen, MD,

Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer  Wu-Wei Lai, MD, Fen-Fen Chen, MD,
Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer:

Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer:
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.
Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor  Song Xu, Qingchun Zhao, Sen Wei, Yi.

Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor  Song Xu, Qingchun Zhao, Sen Wei, Yi.
MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values  Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values  Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers  Yung-Chie Lee, MD, PhD, Yih-Leong Chang, MD, Shi-Ping.

Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers  Yung-Chie Lee, MD, PhD, Yih-Leong Chang, MD, Shi-Ping.
Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment  Tiffany G. Huynh, BA, Vicente Morales-Oyarvide,

Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment  Tiffany G. Huynh, BA, Vicente Morales-Oyarvide,
Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,
Epidermal Growth Factor Receptor Is a Prognosis Predictor in Patients With Esophageal Squamous Cell Carcinoma  Wencheng Zhang, MD, Hongxia Zhu, MD, Xiao.

Epidermal Growth Factor Receptor Is a Prognosis Predictor in Patients With Esophageal Squamous Cell Carcinoma  Wencheng Zhang, MD, Hongxia Zhu, MD, Xiao.
Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report  Tsu-Hui Shiao, MD, Yih-Leong Chang, MD, Chong-Jen Yu, MD, PhD, Yeun-Chung.

Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report  Tsu-Hui Shiao, MD, Yih-Leong Chang, MD, Chong-Jen Yu, MD, PhD, Yeun-Chung.
The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.
Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally.

Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally.

Similar presentations

Ads by Google